Final Results

BIOVENTIX PLC

FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2012

25 SEPTEMBER 2012

Bioventix plc (BVXP) ("Bioventix" or "the Company"), a UK company specialising
in the development and commercial supply of high-affinity monoclonal antibodies
for applications in clinical diagnostics, announces its final results for the
year ended 30 June 2012.

Highlights

* Revenues have grown by 21% compared with the year to 30 June 2011

* Profit after tax increased by 39% compared with the year to 30 June 2011

* Cash balances of GBP2.28m at 30 June 2012 (GBP1.53m at 30 June 2011)

* Final dividend declared of 7.26p (2011: 6.6p)

Chairman and the Chief Executive's report

We are pleased to report the results for the year ended 30 June 2012. Revenues
for the period of £2,383,971 (2011: £1,973,542) have grown by 21% as a result
of increased sales of purified antibodies and increased royalties. Profit
before tax of £1,506,267 (2011: £1,083,620) has increased by 39% due to the
high margin nature of the business, particularly the royalty income and through
continued cost control.

During the year Bioventix's leading vitamin D antibody, vitD3.5H10 moved into
large scale manufacture in response to customer demand and revenue from the
supply of this product has continued to grow during the period. Whilst no
significant commercial vitamin D assays based on vitD3.5H10 are currently in
the market, the Directors remain optimistic that this antibody will generate
revenues for the Company in future periods. The Company has also entered into
additional licensing deals with major diagnostics companies in respect of
vitD3.5H10.

The Company has continued to undertake research and development projects, some
at own-risk and some in collaboration with third parties such as other
diagnostics companies and Universities. A variety of projects are currently in
progress which will increase the number of potential future antibodies.

We are delighted by the continued growth of Bioventix, which operates in a
competitive global market for antibodies and antibody technology. This is only
possible through the skilled work of the scientists and support staff at the
Company and their ability to develop innovative antibody solutions for the
marketplace. We would like to thank them for their continued efforts which
underpin the Company's success.

Bioventix shares are quoted on PLUS Stock Exchange (PLUS-SX) in London. In June
2012, PLUS-SX was acquired by ICAP, a major institutional broking firm which is
listed on the Main Market of the London Stock Exchange. We believe that the
acquisition by ICAP will result in positive developments for PLUS-SX companies
and their shareholders.

The Board of Bioventix is pleased to declare a final dividend of 7.26p per
Ordinary share. The shares will be marked ex-dividend on 3 October 2012 and the
dividend will be paid on 15 October 2012 to shareholders on the register at
close of business on 5 October 2012.


P Harrison
Chief Executive Officer

I J Nicholson
Non-Executive Chairman


For further information, please contact:

Bioventix plc
Peter Harrison
Tel: [phone]

Keith, Bayley, Rogers & Co. Limited
David Coffman
Tel: [phone]


About Bioventix plc

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares (BVXP)
were admitted to trading on PLUS-SX in April 2010.

PUBLICATION OF NON-STATUTORY ACCOUNTS

The financial information set out in this announcement does not constitute
statutory financial statements for the year ended 30 June 2012 or 30 June 2011.
The reports of the auditor on the statutory financial statements for each of
the years ended 30 June 2012 and 30 June 2011 were (i) unqualified; (ii) did
not include references to any matters to which the auditor drew attention by
way of emphasis without qualifying their report; and (iii) did not contain
statements under section 498(2) or (3) of the Companies Act 2006. The statutory
financial statements for the year ended 30 June 2011 have been delivered to the
Registrar of Companies. The statutory financial statements for the year ended
30 June 2012 will be delivered to the Registrar of Companies following the
Company's Annual General Meeting.


                            PROFIT AND LOSS ACCOUNT                            

                        FOR THE YEAR ENDED 30 JUNE 2012                        

                                                             2012          2011
                                                                               
                                                                £             £
                                                                               
TURNOVER                                                2,383,971     1,973,542
                                                                               
Cost of sales                                           (203,579)     (236,315)
                                                                               
GROSS PROFIT                                            2,180,392     1,737,227
                                                                               
Administrative expenses                                 (685,541)     (657,629)
                                                                               
OPERATING PROFIT                                        1,494,851     1,079,598
                                                                               
Interest receivable and similar income                     11,536         4,022
                                                                               
Interest payable and similar charges                        (120)             -
                                                                               
PROFIT ON ORDINARY ACTIVITIES BEFORE                    1,506,267     1,083,620
TAXATION                                                                       
                                                                               
Tax on profit on ordinary activities                    (269,069)     (199,161)
                                                                               
PROFIT FOR THE FINANCIAL YEAR                           1,237,198       884,459
                                                                               

Earnings per share

Basic                                                      24.62p        17.59p
Diluted                                                    24.62p        17.59p

All amounts relate to continuing operations.


There were no recognised gains and losses for 2012 or 2011 other than those
included in the Profit and loss account.



                                 BALANCE SHEET                                 

                              AS AT 30 JUNE 2012                               

                                                     2012                  2011
                                                                               
                                             £          £          £          £
                                                                               
FIXED ASSETS                                                                   
                                                                               
Intangible assets                                  30,000                50,000
                                                                               
Tangible assets                                   442,223               448,871
                                                                               
                                                  472,223               498,871
                                                                               
CURRENT ASSETS                                                                 
                                                                               
Stocks                                  85,687                70,743           
                                                                               
Debtors                                816,182               766,755           
                                                                               
Cash at bank and in hand             2,179,138             1,531,644           
                                                                               
                                     3,081,007             2,369,142           
                                                                               
CREDITORS: amounts falling due       (206,828)             (184,384)           
within one year                                                                
                                                                               
NET CURRENT ASSETS                              2,874,179             2,184,758
                                                                               
TOTAL ASSETS LESS CURRENT LIABILITIES           3,346,402             2,683,629
                                                                               
PROVISIONS FOR LIABILITIES                                                     
                                                                               
Deferred tax                                      (6,716)               (6,237)
                                                                               
NET ASSETS                                      3,339,686             2,677,392
                                                                               
CAPITAL AND RESERVES                                                           
                                                                               
Called up share capital                           251,269               251,269
                                                                               
Capital redemption reserve                          1,231                 1,231
                                                                               
Profit and loss account                         3,087,186             2,424,892
                                                                               
SHAREHOLDERS' FUNDS                             3,339,686             2,677,392



                              CASH FLOW STATEMENT                              

                        FOR THE YEAR ENDED 30 JUNE 2012                        

                                                             2012          2011
                                                                               
                                                                £             £
                                                                               
Net cash flow from operating activities                 1,469,254     1,063,593
                                                                               
Returns on investments and servicing of                    11,416      (93,478)
finance                                                                        
                                                                               
Taxation                                                (241,572)     (203,976)
                                                                               
Capital expenditure and financial investment             (16,700)      (10,738)
                                                                               
Equity dividends paid                                   (574,904)     (524,117)
                                                                               
CASH INFLOW BEFORE FINANCING                              647,494       231,284
                                                                               
Financing                                                       -      (48,725)
                                                                               
INCREASE IN CASH IN THE YEAR                              647,494       182,559



         RECONCILIATION OF NET CASH FLOW TO MOVEMENT IN NET FUNDS/DEBT         

                        FOR THE YEAR ENDED 30 JUNE 2012                        

                                                             2012          2011
                                                                               
                                                                £             £
                                                                               
Increase in cash in the year                              647,494       182,559
                                                                               
MOVEMENT IN NET DEBT IN THE YEAR                          647,494       182,559
                                                                               
Net funds at 1 July 2011                                1,531,644     1,349,085
                                                                               
NET FUNDS AT 30 JUNE 2012                               2,179,138     1,531,644

The Directors of Bioventix plc accept responsibility for this announcement